{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:55:20Z","timestamp":1766087720136},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pituitary adenomas are one type of intracranial tumor, which can be divided into microadenoma (\u2264 1 cm), macroadenoma (&gt; 1 cm), and giant adenoma (\u2265 4 cm) according to their diametral sizes. They are benign, typically slow-progressing, whereas the biological behavior of some of them is invasive, which presents a major clinical challenge. Treatment of some pituitary adenomas is still difficult due to drug resistance or multiple relapses, usually after surgery, medication, and radiation. At present, no clear prediction and treatment biomarkers have been found in pituitary adenomas and some of them do not cause clinical symptoms, so patients are often found to be ill through physical examination, and some are even found through autopsy. With the development of research on pituitary adenomas, the immune response has become a hot spot and may serve as a novel disease marker and therapeutic target.<\/jats:p>\n                <jats:p>The distribution and function of immune cells and their secreted molecules in pituitary adenomas are extremely complex. Researchers found that infiltration of immune cells may have a positive effect on the treatment and prognosis of pituitary adenomas. In this review, we summarized the advance of tumor immunity in pituitary adenomas, revealing the immunity molecules as potential biomarkers as well as therapeutic agents for pituitary adenomas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The immune studies related to pituitary adenomas may help us find relevant immune markers. At the same time, the exploration of immunotherapy also provides new options for the treatment of pituitary adenomas.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-021-02272-9","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T14:03:01Z","timestamp":1622901781000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Research advances on the immune research and prospect of immunotherapy in pituitary adenomas"],"prefix":"10.1186","volume":"19","author":[{"given":"Ding","family":"Nie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyue","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songbai","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"2272_CR1","first-page":"141","volume":"6","author":"G Fabio","year":"2015","unstructured":"Fabio G, et al. Pituitary adenoma and the chemokine network: a systemic view. Front Endocrinol. 2015;6:141.","journal-title":"Front Endocrinol"},{"issue":"7","key":"2272_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrendo.2014.64","volume":"10","author":"A Di Ieva","year":"2014","unstructured":"Di Ieva A, et al. Aggressive pituitary adenomas\u2014diagnosis and emerging treatments. Nat Rev Endocrinol. 2014;10(7):423\u201335. https:\/\/doi.org\/10.1038\/nrendo.2014.64.","journal-title":"Nat Rev Endocrinol"},{"key":"2272_CR3","doi-asserted-by":"publisher","unstructured":"Hansen TM, Batra S, Lim M, et al. Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev.\u00a02014;37(2):279\u201386. https:\/\/doi.org\/10.1007\/s10143-014-0525-y.","DOI":"10.1007\/s10143-014-0525-y"},{"key":"2272_CR4","doi-asserted-by":"publisher","unstructured":"Heaney AP. Clinical review: Pituitary carcinoma: difficult diagnosis and treatment [published correction appears in J Clin Endocrinol Metab. 2012 Mar;97(3):1064]. J Clin Endocrinol Metab. 2011;96(12):3649\u201360. https:\/\/doi.org\/10.1210\/jc.2011-2031.","DOI":"10.1210\/jc.2011-2031"},{"issue":"5","key":"2272_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1078-0432.CCR-18-3486","volume":"26","author":"HR Kemeny","year":"2020","unstructured":"Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, et al. Targeting PD-L1 initiates effective antitumor immunity in a murine model of cushing disease. Clin Cancer Res. 2020;26(5):1141\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3486.","journal-title":"Clin Cancer Res"},{"key":"2272_CR6","doi-asserted-by":"publisher","unstructured":"Dai W, Zhuang Z, Ling H, Yang Y, Hang C. Systematic review and network meta-analysis assess the comparative efficacy and safety of transsphenoidal surgery for pituitary tumor. Neurosurg Rev. 2021;44(1):515\u201327. https:\/\/doi.org\/10.1007\/s10143-020-01240-3.","DOI":"10.1007\/s10143-020-01240-3"},{"issue":"5","key":"2272_CR7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00701-017-3438-z","volume":"160","author":"R Almutairi","year":"2018","unstructured":"Almutairi R, et al. Gross total resection of pituitary adenomas after endoscopic vs. microscopic transsphenoidal surgery: a meta-analysis. Acta Neurochir. 2018;160(5):1005\u201321. https:\/\/doi.org\/10.1007\/s00701-017-3438-z.","journal-title":"Acta Neurochir"},{"issue":"2","key":"2272_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/cancers12020308","volume":"12","author":"LS Lamb","year":"2020","unstructured":"Lamb LS, Sim H-W, McCormack AI. Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature\u2014\u201care we there yet?\u201d. Cancers. 2020;12(2):308. https:\/\/doi.org\/10.3390\/cancers12020308.","journal-title":"Cancers"},{"issue":"1","key":"2272_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.23736\/S0390-5616.18.04419-3","volume":"64","author":"T Maghathe","year":"2020","unstructured":"Maghathe T, Miller WK, Mugge L, Mansour TR, Schroeder J. Immunotherapy and potential molecular targets for the treatment of pituitary adenomas resistant to standard therapy: a critical review of potential therapeutic targets and current developments. J Neurosurg Sci. 2020;64(1):71\u201383. https:\/\/doi.org\/10.23736\/S0390-5616.18.04419-3.","journal-title":"J Neurosurg Sci"},{"issue":"3","key":"2272_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ejca.2011.11.002","volume":"48","author":"Z Suojun","year":"2012","unstructured":"Suojun Z, Feng W, Dongsheng G, Ting L. Targeting Raf\/MEK\/ERK pathway in pituitary adenomas. Eur J Cancer. 2012;48(3):389\u201395. https:\/\/doi.org\/10.1016\/j.ejca.2011.11.002.","journal-title":"Eur J Cancer"},{"key":"2272_CR11","doi-asserted-by":"crossref","unstructured":"Strathmann FG, Borlee G, Born DE, Gonzalez-Cuyar LF, Huber BR, Baird GS.\u00a0Multiplex immunoassays of peptide hormones extracted from formalin-fixed, paraffin-embedded tissue accurately subclassify pituitary adenomas. Clin Chem. 2012;58(2):366\u201374.","DOI":"10.1373\/clinchem.2011.170613"},{"key":"2272_CR12","doi-asserted-by":"publisher","unstructured":"Dragomir MP, Moisoiu V, Manaila R, et al. A holistic perspective: exosomes shuttle between nerves and immune cells in the tumor microenvironment. J Clin Med. 2020;9(11):3529. https:\/\/doi.org\/10.3390\/jcm9113529.","DOI":"10.3390\/jcm9113529"},{"issue":"1","key":"2272_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13578-020-00488-y","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang J, Gu C, Song Q, Zhu M, Xu Y, Xiao M, et al. Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma. Cell Biosci. 2020;10(1):127. https:\/\/doi.org\/10.1186\/s13578-020-00488-y.","journal-title":"Cell Biosci"},{"issue":"1","key":"2272_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s40478-019-0830-3","volume":"7","author":"P Marques","year":"2019","unstructured":"Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun. 2019;7(1):172. https:\/\/doi.org\/10.1186\/s40478-019-0830-3.","journal-title":"Acta Neuropathol Commun"},{"key":"2272_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.smim.2017.06.002","volume":"32","author":"CM Buchta Rosean","year":"2017","unstructured":"Buchta Rosean CM. and M.R. Rutkowski, The influence of the commensal microbiota on distal tumor-promoting inflammation. Semin Immunol. 2017;32:62\u201373. https:\/\/doi.org\/10.1016\/j.smim.2017.06.002.","journal-title":"Semin Immunol"},{"key":"2272_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.conb.2019.10.009","volume":"62","author":"H Hajjo","year":"2020","unstructured":"Hajjo H, Geva-Zatorsky N. Gut microbiota\u2013host interactions now also brain-immune axis. Curr Opin Neurobiol. 2020;62:53\u20139. https:\/\/doi.org\/10.1016\/j.conb.2019.10.009.","journal-title":"Curr Opin Neurobiol"},{"key":"2272_CR17","doi-asserted-by":"publisher","first-page":"119401","DOI":"10.1016\/j.biomaterials.2019.119401","volume":"219","author":"SB Yong","year":"2019","unstructured":"Yong SB, Chung JY, Song Y, Kim J, Ra S, Kim YH. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Biomaterials. 2019;219:119401. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119401.","journal-title":"Biomaterials"},{"key":"2272_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","volume":"65","author":"C Belli","year":"2018","unstructured":"Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22\u201332. https:\/\/doi.org\/10.1016\/j.ctrv.2018.02.004.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2272_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","volume":"368","author":"L Hui","year":"2015","unstructured":"Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368(1):7\u201313. https:\/\/doi.org\/10.1016\/j.canlet.2015.07.039.","journal-title":"Cancer Lett"},{"issue":"10","key":"2272_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/cancers11101605","volume":"11","author":"MD Ilie","year":"2019","unstructured":"Ilie MD, Vasiljevic A, Raverot G, Bertolino P. The microenvironment of pituitary tumors\u2014biological and therapeutic implications. Cancers. 2019;11(10):1605. https:\/\/doi.org\/10.3390\/cancers11101605.","journal-title":"Cancers"},{"key":"2272_CR21","doi-asserted-by":"publisher","DOI":"10.3109\/9780203490884-6","volume-title":"Human Immune System","author":"K Ramaswamy","year":"2003","unstructured":"Ramaswamy K. Human Immune System; 2003."},{"issue":"11","key":"2272_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","volume":"18","author":"L Chiossone","year":"2018","unstructured":"Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671\u201388. https:\/\/doi.org\/10.1038\/s41577-018-0061-z.","journal-title":"Nat Rev Immunol"},{"key":"2272_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.smim.2017.08.002","volume":"31","author":"KJ Malmberg","year":"2017","unstructured":"Malmberg KJ, Carlsten M, Bj\u00f6rklund A, Sohlberg E, Bryceson YT, Ljunggren HG. Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017;31:20\u20139. https:\/\/doi.org\/10.1016\/j.smim.2017.08.002.","journal-title":"Semin Immunol"},{"issue":"7","key":"2272_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","volume":"11","author":"HG Ljunggren","year":"1990","unstructured":"Ljunggren HG, K\u00e4rre K. In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237\u201344. https:\/\/doi.org\/10.1016\/0167-5699(90)90097-S.","journal-title":"Immunol Today"},{"key":"2272_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-030-17864-2_2","volume":"1151","author":"F Garrido","year":"2019","unstructured":"Garrido F. MHC\/HLA Class I Loss in Cancer Cells. Adv Exp Med Biol. 2019;1151:15\u201378. https:\/\/doi.org\/10.1007\/978-3-030-17864-2_2.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"2272_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri.2017.143","volume":"18","author":"CA Dendrou","year":"2018","unstructured":"Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev Immunol. 2018;18(5):325\u201339. https:\/\/doi.org\/10.1038\/nri.2017.143.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2272_CR27","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1073\/pnas.0609692104","volume":"104","author":"T Walzer","year":"2007","unstructured":"Walzer T, Blery M, Chaix J, Fuseri N, Chasson L, Robbins SH, et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A. 2007;104(9):3384\u20139. https:\/\/doi.org\/10.1073\/pnas.0609692104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2272_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2017.00387","volume":"8","author":"S Weil","year":"2017","unstructured":"Weil S, et al. Natural killer group 2D ligand depletion reconstitutes natural killer cell immunosurveillance of head and neck squamous cell carcinoma. Front Immunol. 2017;8:387.","journal-title":"Front Immunol"},{"issue":"1","key":"2272_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58. https:\/\/doi.org\/10.1186\/s13045-017-0430-2.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2272_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883\u201399. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025.","journal-title":"Cell"},{"issue":"8","key":"2272_CR31","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.7150\/thno.53749","volume":"11","author":"A Zhang","year":"2021","unstructured":"Zhang A, Xu Y, Xu H, Ren J, Meng T, Ni Y, et al. Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17. Theranostics. 2021;11(8):3839\u201352. https:\/\/doi.org\/10.7150\/thno.53749.","journal-title":"Theranostics"},{"issue":"3","key":"2272_CR32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12020-020-02478-z","volume":"70","author":"P Marques","year":"2020","unstructured":"Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Dorward N, et al. The role of the tumour microenvironment in the angiogenesis of pituitary tumours. Endocrine. 2020;70(3):593\u2013606. https:\/\/doi.org\/10.1007\/s12020-020-02478-z.","journal-title":"Endocrine"},{"issue":"18","key":"2272_CR33","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3962.","journal-title":"Cancer Res"},{"issue":"1","key":"2272_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69(1):301\u201318. https:\/\/doi.org\/10.1146\/annurev-med-012017-043208.","journal-title":"Annu Rev Med"},{"key":"2272_CR35","doi-asserted-by":"publisher","unstructured":"Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021;28(1-2):5\u201317. https:\/\/doi.org\/10.1038\/s41417-020-0183-x.","DOI":"10.1038\/s41417-020-0183-x"},{"key":"2272_CR36","doi-asserted-by":"publisher","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41(3):1474\u201398. https:\/\/doi.org\/10.1002\/med.2176.","DOI":"10.1002\/med.2176"},{"issue":"10","key":"2272_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/intimm\/dxv034","volume":"27","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. Int Immunol. 2015;27(10):521\u201330. https:\/\/doi.org\/10.1093\/intimm\/dxv034.","journal-title":"Int Immunol"},{"issue":"9","key":"2272_CR38","doi-asserted-by":"publisher","first-page":"e3207","DOI":"10.1210\/clinem\/dgaa449","volume":"105","author":"Z Wang","year":"2020","unstructured":"Wang Z, Guo X, Gao L, Deng K, Lian W, Bao X, et al. The immune profile of pituitary adenomas and a novel immune classification for predicting immunotherapy responsiveness. J Clin Endocrinol Metab. 2020;105(9):e3207\u201323. https:\/\/doi.org\/10.1210\/clinem\/dgaa449.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2272_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11060-013-1354-5","volume":"117","author":"E Aflorei","year":"2014","unstructured":"Aflorei E, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neuro-Oncol. 2014;117(3):379\u201394. https:\/\/doi.org\/10.1007\/s11060-013-1354-5.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"2272_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.17925\/EE.2019.15.1.30","volume":"15","author":"E Varlamov","year":"2019","unstructured":"Varlamov E, McCartney S, Fleseriu M. Functioning pituitary adenomas - current treatment options and emerging medical therapies. Eur Endocrinol. 2019;15(1):30\u201340. https:\/\/doi.org\/10.17925\/EE.2019.15.1.30.","journal-title":"Eur Endocrinol"},{"issue":"3","key":"2272_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11060-020-03476-x","volume":"147","author":"JT Yeung","year":"2020","unstructured":"Yeung JT, Vesely MD, Miyagishima DF. In silico analysis of the immunological landscape of pituitary adenomas. J Neurooncol. 2020;147(3):595\u20138. https:\/\/doi.org\/10.1007\/s11060-020-03476-x.","journal-title":"J Neurooncol"},{"issue":"1","key":"2272_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","volume":"139","author":"PF Wang","year":"2018","unstructured":"Wang PF, Wang TJ, Yang YK, Yao K, Li Z, Li YM, et al. The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol. 2018;139(1):89\u201395. https:\/\/doi.org\/10.1007\/s11060-018-2844-2.","journal-title":"J Neurooncol"},{"issue":"17","key":"2272_CR43","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/1078-0432.CCR-17-2206","volume":"24","author":"MP Salomon","year":"2018","unstructured":"Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, et al. The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing's disease and endocrine-inactive subtypes. Clin Cancer Res. 2018;24(17):4126\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2206.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2272_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case\u2013control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126(1):123\u201335. https:\/\/doi.org\/10.1007\/s00401-013-1084-y.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2272_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11154-020-09561-w","volume":"21","author":"M Fleseriu","year":"2020","unstructured":"Fleseriu M, Popovic V. The journey in diagnosis and treatment, from pituitary adenoma to aggressive pituitary tumors. Rev Endocr Metab Disord. 2020;21(2):201\u20132. https:\/\/doi.org\/10.1007\/s11154-020-09561-w.","journal-title":"Rev Endocr Metab Disord"},{"key":"2272_CR46","doi-asserted-by":"crossref","unstructured":"Principe, M., et al., Immune landscape of pituitary neuroendocrine tumours reveals association between macrophages and gonadotroph-tumour invasion. J Clin Endocrinol Metab, 2020.","DOI":"10.1210\/clinem\/dgaa520"},{"key":"2272_CR47","doi-asserted-by":"publisher","unstructured":"Principe M, Chanal M, Ilie MD, et al. Immune landscape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion. J Clin Endocrinol Metab. 2020;105(11):dgaa520. https:\/\/doi.org\/10.1210\/clinem\/dgaa520.","DOI":"10.1210\/clinem\/dgaa520"},{"issue":"3","key":"2272_CR48","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","volume":"26","author":"JQ Lu","year":"2015","unstructured":"Lu JQ, Adam B, Jack AS, Lam A, Broad RW, Chik CL. Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas. Endocr Pathol. 2015;26(3):263\u201372. https:\/\/doi.org\/10.1007\/s12022-015-9383-6.","journal-title":"Endocr Pathol"},{"issue":"47","key":"2272_CR49","doi-asserted-by":"publisher","first-page":"76565","DOI":"10.18632\/oncotarget.12088","volume":"7","author":"Y Mei","year":"2016","unstructured":"Mei Y, Bi WL, Greenwald NF, du Z, Agar NYR, Kaiser UB, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016;7(47):76565\u201376. https:\/\/doi.org\/10.18632\/oncotarget.12088.","journal-title":"Oncotarget"},{"key":"2272_CR50","doi-asserted-by":"publisher","unstructured":"Sato M, Tamura R, Tamura H, et al. Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. J Clin Med. 2019;8(5):695. https:\/\/doi.org\/10.3390\/jcm8050695.","DOI":"10.3390\/jcm8050695"},{"issue":"3","key":"2272_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s12020-019-02145-y","volume":"67","author":"D Iacovazzo","year":"2020","unstructured":"Iacovazzo D, Chiloiro S, Carlsen E, Bianchi A, Giampietro A, Tartaglione T, et al. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine. 2020;67(3):651\u20138. https:\/\/doi.org\/10.1007\/s12020-019-02145-y.","journal-title":"Endocrine"},{"issue":"3","key":"2272_CR52","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11060-020-03636-z","volume":"149","author":"W Zhou","year":"2020","unstructured":"Zhou W, Zhang C, Zhang D, Peng J, Ma S, Wang X, et al. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. J Neurooncol. 2020;149(3):473\u201387. https:\/\/doi.org\/10.1007\/s11060-020-03636-z.","journal-title":"J Neurooncol"},{"issue":"27","key":"2272_CR53","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1038\/s41388-019-0779-5","volume":"38","author":"S Barry","year":"2019","unstructured":"Barry S, Carlsen E, Marques P, Stiles CE, Gadaleta E, Berney DM, et al. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene. 2019;38(27):5381\u201395. https:\/\/doi.org\/10.1038\/s41388-019-0779-5.","journal-title":"Oncogene"},{"issue":"1","key":"2272_CR54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1210\/jc.2009-1583","volume":"95","author":"I Lupi","year":"2010","unstructured":"Lupi I, Manetti L, Caturegli P, Menicagli M, Cosottini M, Iannelli A, et al. Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma. J Clin Endocrinol Metab. 2010;95(1):289\u201396. https:\/\/doi.org\/10.1210\/jc.2009-1583.","journal-title":"J Clin Endocrinol Metab"},{"key":"2272_CR55","unstructured":"Gang, H., et al., The study on expression and relationship between matrix metalloproteinase-2 and CD147 in invasive pituitary adenomas. Chinese J Nervous Ment Dis. 2005."},{"key":"2272_CR56","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/j.wneu.2020.09.031","volume":"144","author":"G Zhao","year":"2020","unstructured":"Zhao G, Chen W, He J, Cui C, Zhao L, Zhao Y, et al. Analysis of cyclooxygenase 2, programmed cell death ligand 1, and arginase 1 expression in human pituitary adenoma. World Neurosur. 2020;144:e660\u201373. https:\/\/doi.org\/10.1016\/j.wneu.2020.09.031.","journal-title":"World Neurosur"},{"issue":"6","key":"2272_CR57","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/030089169007600605","volume":"76","author":"ML Rossi","year":"1990","unstructured":"Rossi ML, Jones NR, Esiri MM, Havas L, Izzi MA, Coakham HB. Mononuclear cell infiltrate and HLA-Dr expression in 28 pituitary adenomas. Tumori. 1990;76(6):543\u20137. https:\/\/doi.org\/10.1177\/030089169007600605.","journal-title":"Tumori"},{"issue":"5","key":"2272_CR58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/01616412.2017.1296653","volume":"39","author":"V Briceno","year":"2017","unstructured":"Briceno V, Zaidi HA, Doucette JA, Onomichi KB, Alreshidi A, Mekary RA, et al. Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol Res. 2017;39(5):387\u201398. https:\/\/doi.org\/10.1080\/01616412.2017.1296653.","journal-title":"Neurol Res"},{"key":"2272_CR59","doi-asserted-by":"publisher","unstructured":"Ilie MD, Vasiljevic A, Raverot G, Bertolino P. The microenvironment of pituitary tumors-biological and therapeutic implications. Cancers (Basel). 2019;11(10):1605. https:\/\/doi.org\/10.3390\/cancers11101605.","DOI":"10.3390\/cancers11101605"},{"issue":"6","key":"2272_CR60","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.mehy.2013.03.011","volume":"80","author":"L Qiu","year":"2013","unstructured":"Qiu L, Yang J, Wang H, Zhu Y, Wang Y, Wu Q. Expression of T-helper-associated cytokines in the serum of pituitary adenoma patients preoperatively and postperatively. Med Hypotheses. 2013;80(6):781\u20136. https:\/\/doi.org\/10.1016\/j.mehy.2013.03.011.","journal-title":"Med Hypotheses"},{"issue":"2","key":"2272_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2265.1996.d01-1554.x","volume":"45","author":"VL Green","year":"1996","unstructured":"Green VL, Atkin SL, Speirs V, Jeffreys RV, Landolt AM, Mathew B, et al. Cytokine expression in human anterior pituitary adenomas. Clin Endocrinol (Oxf). 1996;45(2):179\u201385. https:\/\/doi.org\/10.1046\/j.1365-2265.1996.d01-1554.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2272_CR62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202(1):8\u201332. https:\/\/doi.org\/10.1111\/j.0105-2896.2004.00204.x.","journal-title":"Immunol Rev"},{"issue":"9","key":"2272_CR63","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1210\/jcem.84.9.6005","volume":"84","author":"LJ Hofland","year":"1999","unstructured":"Hofland LJ, de Herder WW, Waaijers M, Zuijderwijk J, Uitterlinden P, van Koetsveld P, et al. Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. J Clin Endocrinol Metab. 1999;84(9):3336\u201343. https:\/\/doi.org\/10.1210\/jcem.84.9.6005.","journal-title":"J Clin Endocrinol Metab"},{"key":"2272_CR64","doi-asserted-by":"publisher","first-page":"585880","DOI":"10.3389\/fimmu.2020.585880","volume":"11","author":"P Gough","year":"2020","unstructured":"Gough P, Myles IA. Tumor necrosis factor receptors: pleiotropic signaling complexes and their differential effects. Front Immunol. 2020;11:585880. https:\/\/doi.org\/10.3389\/fimmu.2020.585880.","journal-title":"Front Immunol"},{"key":"2272_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(03)00841-2","volume":"321","author":"MS Nanes","year":"2003","unstructured":"Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene. 2003;321:1\u201315. https:\/\/doi.org\/10.1016\/S0378-1119(03)00841-2.","journal-title":"Gene"},{"issue":"22","key":"2272_CR66","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1158\/1078-0432.CCR-18-0472","volume":"24","author":"H Zhu","year":"2018","unstructured":"Zhu H, Guo J, Shen Y, Dong W, Gao H, Miao Y, et al. Functions and mechanisms of tumor necrosis factor-\u03b1 and noncoding RNAs in bone-invasive pituitary adenomas. Clin Cancer Res. 2018;24(22):5757\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0472.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2272_CR67","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.3390\/ijms12064165","volume":"12","author":"Z Xiao","year":"2011","unstructured":"Xiao Z, Liu Q, Mao F, Wu J, Lei T. TNF-\u03b1-induced VEGF and MMP-9 expression promotes hemorrhagic transformation in pituitary adenomas. Int J Mol Sci. 2011;12(6):4165\u201379. https:\/\/doi.org\/10.3390\/ijms12064165.","journal-title":"Int J Mol Sci"},{"key":"2272_CR68","doi-asserted-by":"publisher","first-page":"7490585","DOI":"10.1155\/2018\/7490585","volume":"2018","author":"B Glebauskiene","year":"2018","unstructured":"Glebauskiene B, et al. Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma. Biomed Res Int. 2018;2018:7490585.","journal-title":"Biomed Res Int"},{"issue":"3","key":"2272_CR69","doi-asserted-by":"publisher","first-page":"e13085","DOI":"10.1111\/aji.13085","volume":"81","author":"AK Kalsi","year":"2019","unstructured":"Kalsi AK, Halder A, Jain M, Chaturvedi PK, Mathew M, Sharma JB. Association of raised levels of IL-4 and anti-TPO with hyperprolactinemia. Am J Reprod Immunol. 2019;81(3):e13085. https:\/\/doi.org\/10.1111\/aji.13085.","journal-title":"Am J Reprod Immunol"},{"issue":"4","key":"2272_CR70","doi-asserted-by":"publisher","first-page":"R241","DOI":"10.1530\/JME-17-0026","volume":"58","author":"M Sapochnik","year":"2017","unstructured":"Sapochnik M, Fuertes M, Arzt E. Programmed cell senescence: role of IL-6 in the pituitary. J Mol Endocrinol. 2017;58(4):R241\u2013r253. https:\/\/doi.org\/10.1530\/JME-17-0026.","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2272_CR71","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1210\/endo.132.1.8419142","volume":"132","author":"E Arzt","year":"1993","unstructured":"Arzt E, Buric R, Stelzer G, Stalla J, Sauer J, Renner U, et al. Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6. Endocrinology. 1993;132(1):459\u201367. https:\/\/doi.org\/10.1210\/endo.132.1.8419142.","journal-title":"Endocrinology"},{"issue":"11","key":"2272_CR72","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF03401765","volume":"4","author":"N Takahashi","year":"1998","unstructured":"Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, et al. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med. 1998;4(11):707\u201314. https:\/\/doi.org\/10.1007\/BF03401765.","journal-title":"Mol Med"},{"key":"2272_CR73","doi-asserted-by":"publisher","unstructured":"Kishore C, Bhadra P.\u00a0Bhadra, Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur J Pharmacol.\u00a02021;893:173819. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173819.","DOI":"10.1016\/j.ejphar.2020.173819"},{"key":"2272_CR74","doi-asserted-by":"publisher","unstructured":"Filin IY, Solovyeva VV, Kitaeva KV, Rutland CS, Rizvanov AA. Current trends in cancer immunotherapy. Biomedicines. 2020;8(12):621. https:\/\/doi.org\/10.3390\/biomedicines8120621.","DOI":"10.3390\/biomedicines8120621"},{"key":"2272_CR75","doi-asserted-by":"publisher","first-page":"608422","DOI":"10.3389\/fendo.2020.608422","volume":"11","author":"C Dai","year":"2020","unstructured":"Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020;11:608422. https:\/\/doi.org\/10.3389\/fendo.2020.608422.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2272_CR76","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","volume":"75","author":"Z Sun","year":"2015","unstructured":"Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, et al. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015;75(8):1635\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3016.","journal-title":"Cancer Res"},{"issue":"4","key":"2272_CR77","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.immuni.2019.03.004","volume":"50","author":"SC Wei","year":"2019","unstructured":"Wei SC, et al. Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states. Immunity. 2019;50(4):1084\u20131098.e10.","journal-title":"Immunity"},{"issue":"12","key":"2272_CR78","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186(12):3225\u201335. https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.020.","journal-title":"Am J Pathol"},{"key":"2272_CR79","doi-asserted-by":"publisher","unstructured":"Weiner DM, Durgin JS, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: part II, current and future approaches. J Am Acad Dermatol. 2021;84(3):597\u2013604. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.026.","DOI":"10.1016\/j.jaad.2020.12.026"},{"issue":"1","key":"2272_CR80","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1182\/blood-2006-11-060087","volume":"110","author":"F Tsushima","year":"2007","unstructured":"Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood. 2007;110(1):180\u20135. https:\/\/doi.org\/10.1182\/blood-2006-11-060087.","journal-title":"Blood"},{"issue":"127","key":"2272_CR81","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"J Taube","year":"2012","unstructured":"Taube J, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.","journal-title":"Sci Transl Med"},{"issue":"4","key":"2272_CR82","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"2272_CR83","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1055\/s-0034-1369961","volume":"139","author":"S Fischli","year":"2014","unstructured":"Fischli S, Allelein S, Zander T, Henzen C. Endocrinologic side effects of oncologic treatment with anti-CTLA-4-antibodies. Dtsch Med Wochenschr. 2014;139(19):996\u20131000. https:\/\/doi.org\/10.1055\/s-0034-1369961.","journal-title":"Dtsch Med Wochenschr"},{"issue":"2","key":"2272_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","volume":"20","author":"P Sharma","year":"2020","unstructured":"Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20(2):75\u20136. https:\/\/doi.org\/10.1038\/s41577-020-0275-8.","journal-title":"Nat Rev Immunol"},{"key":"2272_CR85","doi-asserted-by":"crossref","unstructured":"Kim DY, Kim PH, Suh CH, Kim KW, Kim HS. Immune checkpoint inhibitors with or without radiotherapy in non-small cell lung cancer patients with brain metastases: a systematic review and meta-analysis. Diagnostics (Basel). 2020;10(12):1098.","DOI":"10.3390\/diagnostics10121098"},{"key":"2272_CR86","doi-asserted-by":"publisher","unstructured":"Sato M, Tamura R, Tamura H, et al. Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. J Clin Med. 2019;8(5):695. https:\/\/doi.org\/10.3390\/jcm8050695.","DOI":"10.3390\/jcm8050695"},{"issue":"1","key":"2272_CR87","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-20-0151","volume":"184","author":"B Sol","year":"2021","unstructured":"Sol B, de Filette JMK, Awada G, Raeymaeckers S, Aspeslagh S, Andreescu CE, et al. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment? Eur J Endocrinol. 2021;184(1):K1\u2013k5. https:\/\/doi.org\/10.1530\/EJE-20-0151.","journal-title":"Eur J Endocrinol"},{"key":"2272_CR88","doi-asserted-by":"publisher","first-page":"664883","DOI":"10.3389\/fonc.2021.664883","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Wang D, Wu W, Lu H. Molecular characteristics of genes and the immune microenvironment of a rare chest malignant tumor (pulmonary clear cell sarcoma): a case report. Front Oncol. 2021;11:664883. https:\/\/doi.org\/10.3389\/fonc.2021.664883.","journal-title":"Front Oncol"},{"issue":"4","key":"2272_CR89","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000100405","volume":"13","author":"SM Hazrati","year":"2006","unstructured":"Hazrati SM, Aghazadeh J, Mohtarami F, Abouzari M, Rashidi A. Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens: a case report. Neuroimmunomodulation. 2006;13(4):205\u20138. https:\/\/doi.org\/10.1159\/000100405.","journal-title":"Neuroimmunomodulation"},{"issue":"1","key":"2272_CR90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14735\/amko202015","volume":"33","author":"R Lakom\u00fd","year":"2020","unstructured":"Lakom\u00fd R, Poprach A, Kazda T. Management of immune-related endocrinopathies in anticancer treatment with checkpoint inhibitors. Klin Onkol. 2020;33(1):15\u20139. https:\/\/doi.org\/10.14735\/amko202015.","journal-title":"Klin Onkol"},{"issue":"2","key":"2272_CR91","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocrine-related Cancer. 2019;26(2):G1\u2013G18. https:\/\/doi.org\/10.1530\/ERC-18-0320.","journal-title":"Endocrine-related Cancer"},{"issue":"2","key":"2272_CR92","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687\u201395. https:\/\/doi.org\/10.1172\/JCI67313.","journal-title":"J Clin Invest"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02272-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T14:04:01Z","timestamp":1622901841000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02272-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02272-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}